Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease
Sare Verstockt(KU Leuven), Séverine Vermeire(KU Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), Maaike Vancamelbeke(KU Leuven), Gert De Hertogh(KU Leuven), Isabelle Cleynen(Universidad Carlos III de Madrid), Kathleen Machiels(KU Leuven)
Cited by 84
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k